PALM BEACH, Florida, October 19, 2017 /PRNewswire/ —
A current trend in the healthcare industry is expansion and growth of several healthcare domains and growing demand for innovative healthcare solutions for the aging population. Healthcare facilities seem to be focusing on a shift to become patient-centric service providers. There are several notable changes in the industry of late such as the entry of new telemedicine solutions, new clinical trials and studies, the development of new treatment therapies and techniques, improvements in infrastructure and the availability of skilled professionals. Active companies in the healthcare industry with market performance and recent developments include Medical Innovation Holdings, Inc. (OTC: MIHI), TransEnterix, Inc. (NYSE: TRXC) (AMEX:TRXC), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Protalix BioTherapeutics, Inc. (NYSE: PLX) (AMEX: PLX), Acadia Healthcare Company, Inc. (NASDAQ: ACHC).
Medical Innovation Holdings, Inc. (OTC: MIHI) today announces its manufacturing agreement with MDI Source, a Georgia-based company serving the technology industry for over 30 years. Per the agreement, MDI will manufacture customized telemedicine equipment to fit the footprint of any doctor’s office that signs up to utilize MIHI’s telemedicine practice. This arrangement will allow MIHI to offer these offices a variety of telemedicine equipment that supports the shift toward a blend of in-office and virtual visits. Coupling MDI’s hardware with MIHI’s EMR/PMS software solution provides rural clinics a comprehensive solution unmatched in the marketplace. Additionally, MDI will provide various levels of technical support and services to MIHI clients, ensuring world-class service with world-class products. Read this and more news for MIHI at http://www.marketnewsupdates.com/news/mihi.html “When we entered this marketplace, the cost for telemedicine workstations were significantly high,” says MIHI CEO Jake Sanchez. “This agreement with MDI is a game changer for MIHI and the marketplace, as we can now offer feature rich and user friendly comprehensive EMP/PMS software solutions at half the price. Our business plan is to subsidize a significant portion of the cost, if not 100%, of the telemedicine stations for our rural primary clinics that sign up and register to utilize our network of specialists. We want to make it as easy as possible for the rural clinics to join up with us.”
In other Healthcare market activity of note from trading on yesterday:
TransEnterix, Inc. (NYSE: TRXC) (AMEX:TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, last week announced the Company has received FDA 510(k) clearance for the Senhance™ Surgical Robotic System. “The clearance of the Senhance System in the US is a milestone in the progress of robotics and is expected to deliver improvement in the efficacy, value and choices offered to patients, surgeons and hospitals,” said Todd M. Pope, President and Chief Executive Officer of TransEnterix. “Millions of surgical procedures in the US are performed each year laparoscopically with basic manual tools that limit surgeons’ capability, comfort and control. New choices are needed that enhance the senses, control and comfort of the surgeon, minimize the invasiveness of surgery for the patient, and maximize value for the hospital. Senhance is this new choice.”
Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) closed up over 36% on Wednesday at $19.67 with over 19.6 million shares traded by the market close and was also up slightly in afterhours trading. The company recently announced the oral presentation of interim data from a Phase 2 clinical study evaluating poziotinib in EGFR Exon 20 Mutant Non-Small-Cell Lung Cancer (NSCLC) by scientists from the MD Anderson Cancer Center which was presented in Yokohama, Japan, October 15-18, 2017. The Company will hold a conference call tomorrow, October 18th, at 8:30 a.m. EDT/5:30 a.m. PDT with Dr. John Heymach, M.D., Ph.D., Chairman, Professor, and David Bruton Junior Chair in Cancer Research, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, to discuss his study results. “These data are remarkable for NSCLC patients with exon 20 insertion mutations,” said John Heymach, M.D., Ph.D., The University of Texas MD Anderson Cancer Center.
Protalix BioTherapeutics, Inc . (NYSE: PLX) (AMEX: PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, yesterday announced an Ex-US license and collaboration agreement with Chiesi Farmaceutici S.p.A., or Chiesi, for pegunigalsidase alfa, or PRX-102, the Company’s chemically modified version of the recombinant protein alpha-Galactosidase-A protein that is currently being evaluated in phase III clinical trials for the treatment of Fabry disease. PRX-102 has demonstrated a significantly enhanced circulatory half-life and higher enzyme activity in the target organs affected by Fabry disease when compared to currently available versions of the molecule, and strong positive safety and efficacy data from its completed phase I/II clinical trial.
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) yesterday announced that it will release its third quarter 2017 earnings on Tuesday, October 24, 2017, after the close of the market. Acadia will conduct a conference call with institutional investors and analysts at 9:00 a.m. ET on Wednesday, October 25, 2017. Additionally, a live broadcast of the earnings conference call will be available at http://www.acadiahealthcare.com in the “Investors” section of the website. The webcast of the conference call will be available through November 7, 2017.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated three thousand dollars for news coverage of the current press releases issued by Medical Innovation Holdings, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Contact Information : Media Contact email: firstname.lastname@example.org